SOX2 Gene Amplification and Overexpression is Linked to HPV-positive Vulvar Carcinomas. by Gut, André et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
SOX2 Gene Amplification and Overexpression is Linked to HPV-positive
Vulvar Carcinomas.
Gut, André; Moch, Holger; Choschzick, Matthias
Abstract: SOX2 (SRY-related HMG-box 2) belongs to the SOX gene family of high-mobility transcription
factors indispensably involved in gene regulation in pluripotent stem cells and neural differentiation.
SOX2 copy number increases have been frequently reported in various types of squamous cell cancer. To
better understand the effect of SOX2 aberrations on vulvar cancer phenotype and patient prognosis, we
analyzed SOX2 copy number changes using fluorescence in situ hybridization and SOX2 expression by
immunohistochemistry in 55 squamous cell carcinomas of the vulva. SOX2 amplification was found in
20.8% of tumors; 27.3% of vulvar carcinomas showed SOX2 protein overexpression. SOX2 amplification
was correlated with SOX2 overexpression in our data set (P<0.01). Amplification of the SOX2 locus
was associated with high tumor grade (P<0.05) and human papillomavirus (HPV) positivity (P<0.01).
SOX2-amplified tumors showed more frequently a basaloid phenotype than nonamplified carcinomas.
SOX2 protein overexpression was also correlated with basaloid phenotype and positive HPV status of
vulvar carcinomas (P<0.05, each). SOX2 amplification and expression were not associated with patient
overall survival. In conclusion, SOX2 copy number increases are detectable in a substantial proportion
of high-grade HPV-positive vulvar carcinomas with basaloid differentiation. Our study provides further
evidence for different molecular alterations in HPV-positive and HPV-negative vulvar carcinomas.
DOI: https://doi.org/10.1097/PGP.0000000000000388
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-142984
Journal Article
Published Version
Originally published at:
Gut, André; Moch, Holger; Choschzick, Matthias (2018). SOX2 Gene Amplification and Overexpression is
Linked to HPV-positive Vulvar Carcinomas. International Journal of Gynecological Pathology, 37(1):68-
73.
DOI: https://doi.org/10.1097/PGP.0000000000000388
International Journal of Gynecological Pathology
00:1–6, Lippincott Williams & Wilkins, Baltimore
Copyright r 2017 by the International Society of Gynecological Pathologists
Original Article
SOX2 Gene Amplification and Overexpression is Linked to
HPV-positive Vulvar Carcinomas
Andre´ Gut, M.D., Holger Moch, M.D., and Matthias Choschzick, M.D.
Summary: SOX2 (SRY-related HMG-box 2) belongs to the SOX gene family of high-
mobility transcription factors indispensably involved in gene regulation in pluripotent
stem cells and neural diﬀerentiation. SOX2 copy number increases have been frequently
reported in various types of squamous cell cancer. To better understand the eﬀect of
SOX2 aberrations on vulvar cancer phenotype and patient prognosis, we analyzed
SOX2 copy number changes using ﬂuorescence in situ hybridization and SOX2
expression by immunohistochemistry in 55 squamous cell carcinomas of the vulva.
SOX2 ampliﬁcation was found in 20.8% of tumors; 27.3% of vulvar carcinomas
showed SOX2 protein overexpression. SOX2 ampliﬁcation was correlated with SOX2
overexpression in our data set (Po0.01). Ampliﬁcation of the SOX2 locus was
associated with high tumor grade (Po0.05) and human papillomavirus (HPV) positivity
(Po0.01). SOX2-ampliﬁed tumors showed more frequently a basaloid phenotype than
nonampliﬁed carcinomas. SOX2 protein overexpression was also correlated with
basaloid phenotype and positive HPV status of vulvar carcinomas (Po0.05, each).
SOX2 ampliﬁcation and expression were not associated with patient overall survival. In
conclusion, SOX2 copy number increases are detectable in a substantial proportion of
high-grade HPV-positive vulvar carcinomas with basaloid diﬀerentiation. Our study
provides further evidence for diﬀerent molecular alterations in HPV-positive and HPV-
negative vulvar carcinomas. Key Words: SOX2—Vulvar cancer—Ampliﬁcation—
prognosis.
Gene ampliﬁcation is a key mechanism for protein
overexpression and oncogene activation in tumor
cells (1). Ampliﬁed oncogenes are markers of general
genomic instability as the base for the development of
further genomic aberrations. Recurrent chromosomal
gains in vulvar cancer have been found at 1q, 3q, 4p,
5p, 8p, 8q, and 12q (2–6). Possible candidate targets
at 3q are human telomerase RNA and the PIK3CA
gene. MYC oncogene is the potential target of the 8q
ampliﬁcation in vulvar cancer. Growdon et al. (7)
observed EGFR ampliﬁcations in 12% of vulvar
carcinomas with adverse prognosis.
The SOX2 gene is located on chromosome 3q26.33
and codes for a 317-amino acid protein that belongs
to the SOX2 gene family of transcription factors (8).
Together with other proteins SOX2 is crucial in the
maintenance of pluripotency in embryonic stem
cells (9). In cooperation with Oct4, c-Myc, and
Klf4, SOX2 is capable of reprograming diﬀerentiated
cells into an induced pluripotent stem cell-like
phenotype (10). Ampliﬁcation and overexpression
of SOX2 has been reported in a wide variety of
cancers, including squamous cell carcinomas (SCC)
of various origins (11). Besides genomic alterations,
human papillomavirus (HPV) infection plays an
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important role in vulvar carcinoma initiation (12).
Approximately one third to two thirds of all vulvar
tumors are related to HPV (predominantly HPV type
16) (13). However, a substantial proportion of
vulvar cancers are not HPV related, especially in
elderly women (14). HPV-negative tumors are fre-
quently TP53 mutated, as shown in former stud-
ies (15). Although still controversial, it is generally
assumed that the prognosis in HPV-related tumors is
better than that in non-papillomavirus-associated
carcinomas.
To improve our understanding of SOX2 copy
number increases and protein expression in vulvar
cancer, we analyzed 55 vulvar tumors with clinical
follow-up data by immunohistochemistry (IHC) and
ﬂuorescence in situ hybridization (FISH). The results
suggest a possible role of SOX2 copy number changes
in the progression and development of HPV-related
vulvar carcinomas.
METHODS
A total of 55 formalin-ﬁxed (buﬀered neutral
aqueous 4% solution), paraﬃn-embedded squamous
cell vulvar carcinomas were available from the
Department of Pathology and Molecular Pathology,
University Hospital Zurich, Switzerland, between
2008 and 2014. The median patient age was 68.9
years (range, 37–89 y). Data were retrieved from
patients’ records, the tumor registry, and death
certiﬁcates. Clinicopathologic factors were evaluated
by reviewing medical charts and pathologic reports.
Clinical outcome was followed up from the date of
primary surgery to the date of death or last
documented visit in our archive system. Permission
for performing the study was obtained from the local
ethics committee.
The histology of all tumors was reevaluated by 1
experienced gynecopathologist (M.C.) and classiﬁed
according to WHO as keratinizing SCC, nonkerati-
nizing SCC, and basaloid SCC (16,17). The criteria
for classiﬁcation as basaloid SCC were composition
of immature cells with scanty cytoplasm resembling
basal cells of the epidermis and no or only little
keratinization. The tumors were graded according to
recommendations of the Gynecologic Oncology
Group into 3 grades: G1, no undiﬀerentiated cells;
G2, <50% undiﬀerentiated cells; and G3, Z50%
undiﬀerentiated tumor cells (18).
Tissue microarray construction was as described
previously (19). Brieﬂy, tissue cylinders with a
diameter of 0.6mm and a height of 3 to 4mm were
punched from representative tumor areas of a
‘‘donor’’ tissue block using a custom-built instru-
ment. They were then brought into 1 recipient
paraﬃn block containing 2 representative tissue spots
of 55 individual samples.
SOX2 FISH Analysis
The probe for analysis of SOX2 was provided by
ZytoVision GmbH (Germany). The probe combina-
tion was SOX2 (ZyGreen)/centromere 3 (ZyOrange).
Slides dedicated to dual-color FISH analysis were
prepared according to recommendations of the
manufacturer. Evaluation of SOX2 ampliﬁcation
status was performed as follows: for each tissue spot,
the predominant gene and centromere copy numbers
in the tumor cell nuclei were estimated. A tumor was
considered ampliﬁed if the ratio of gene/centromere
was Z2.0 or by the presence of gene clusters. Ratios
>1.0 and <2.0 were considered as gains and a ratio
r1.0 was considered normal (20).
SOX2 IHC
Commercially available antibodies raised against
SOX2 (clone EPR3131, 1:100; Epitomics Inc.) were
used on a Ventana Benchmark automated staining
system (Ventana Medical Systems Inc., Tucson, AZ).
For SOX2, only nuclear staining was regarded as
speciﬁc. IHC was evaluated in 2 cores per tumor.
SOX2 staining intensity and the fraction of stained
tumor cells were recorded for each tissue spot. Staining
intensity was estimated on a 4-step scale (0, no staining;
1+, faint intensity; 2+, moderate intensity; 3+,
strongest intensity). The fraction of stained cells was
scored according to the following criteria: score 0, no
stained cells; score 1, r25% stained cells; score 2,
r50% stained cells; score 3, r75% stained cells; and
score 4, >75% stained cells. A ﬁnal IHC result was
obtained from these scores: negative, no staining at all;
weak, intensity 1+, or intensity 2+ inr50% of cells,
or intensity 3+ in r25% of cells; moderate, intensity
2+ in 50% to 75% of cells, or intensity 3+ in 25% to
50% of cells; strong, intensity 2+ in >75% of cells, or
intensity 3+ in >50% of cells. Both negative and
weak as well as moderate and strong SOX2 expressions
were combined with low-level and high-level expression
patterns for further analyses.
HPV Detection
Analysis of the tumor HPV status was carried out
with RNA in situ hybridization, utilizing speciﬁc
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probes against pan HPV and HPV 16 [ViewRNAeZ-
L ISH detection kit (PN 19500) from Aﬀymetrix Inc.,
Santa Clara, CA]. HPV 16 (PN DVA1-17255)
targeted E6/E7 of HPV 16 and pan HPV (PN
DVA1-17029) targeted E6/E7 of 14 high-risk HPV
strains (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66,
and 68). All probe sets were diluted 1:40, except the
pan HPV 1 (1:200); the probes were hybridized for 3
hours using the ‘‘View RNA red detection’’ protocol
on the Leica Bond RX (21). Appropriate positive and
negative controls were applied by manufacturer
recommendations.
Statistics
The Pearson w2 test and Student t test were used to
study the relationship between SOX2 and clinicopa-
thologic parameters. The survival eﬀect of SOX2 was
assessed by the Kaplan-Meier curves and log-rank
tests. Analysis was performed using R statistical
software package for Windows (version 2.7.2, R
Foundation for statistical computing).
RESULTS
SOX2 FISH and IHC
A total of 48 cancer samples were assessable by
FISH on the tissue microarray (Table 1). Overall,
SOX2 copy number increases were found in 10
(20.8%) vulvar cancers. Figure 1 displays a repre-
sentative example with SOX2 ampliﬁcation. All
tumors with copy number increases showed low-
level ampliﬁcation with a signal ratio of 2 to 10 per
nucleus. Immunohistochemical examination of SOX2
expression was possible in 55 vulvar carcinomas
(Table 1). The expression pattern was always
nuclear. Figures 2A–C illustrate representative exam-
ples with low-level and high-level SOX2 expression
according to our predeﬁned criteria. An overall
27.3% of vulvar carcinomas showed a strong SOX2
expression. SOX2 expression was statistically signiﬁ-
cantly related to SOX2 gene copy number in the
present cohort of vulvar cancers. Seven out of 10
vulvar cancers with SOX2 ampliﬁcation exhibited
a strong nuclear SOX2 expression signal
(Po0.01, Table 2). However, high-level protein
expression was also detectable in 6 of 32 vulvar
carcinomas without SOX2 ampliﬁcation.
Association With Clinicopathologic Features
Table 1 summarizes the association of SOX2 copy
number increases and SOX2 protein expression with
clinicopathologic parameters of vulvar carcinomas.
SOX2 copy number increases were related to tumor
grade and HPV status of vulvar carcinomas. Ampli-
ﬁcation of SOX2 was more frequent in poorly
diﬀerentiated (Po0.05; G1+G2 vs. G3) and HPV-
positive (Po0.05) tumors. There was a tendency for
SOX2-ampliﬁed cancers to show more frequently a
basaloid phenotype, but this result was not signiﬁcant
(20% vs. 7.9%). However, we observed a statistically
signiﬁcant connection between SOX2 protein over-
expression and basaloid phenotype of vulvar carci-
nomas (Po0.05). Furthermore, SOX2 expression
was linked to positive HPV status of vulvar cancer
(Po0.05). There was no statistical correlation be-
tween higher tumor grade and HPV positivity (50%
vs. 24.3%). The last result did not reach statistical
signiﬁcance.
There was also no association of SOX2 copy
number alterations or SOX2 expression with patient
age, pN category, or tumor stage.
We examined the relationship between SOX2
expression and ampliﬁcation in vulvar carcinomas
and overall survival of vulvar cancer patients. There
was no clear inﬂuence of these parameters on overall
survival in our analysis (Fig. 3).
DISCUSSION
In our study, we detected frequent SOX2 ampliﬁ-
cation and SOX2 protein overexpression in vulvar
carcinomas. SOX2 copy number increases correlated
with SOX2 overexpression, suggesting that SOX2
gene ampliﬁcation is the main mechanism for SOX2
overexpression in vulvar cancer. Interestingly, 6
tumors with SOX2 overexpression were not ampliﬁed
in our analysis. In these carcinomas other mecha-
nisms than ampliﬁcation are presumably responsible
for SOX2 upregulation. Activity of SOX2 is con-
trolled by various translational and posttranslational
modiﬁcations. At the translational level, inhibitory
microRNAs play a pivotal role and could be a
mechanism for elevated SOX2 levels in the absence of
ampliﬁcation (22).
At present, there are no data available in the
literature on SOX2 ampliﬁcation in vulvar cancer,
but our observations are comparable to previous
reports on SCC of the esophagus, lung, head and
neck, and other localizations (20,23–25). These
studies describe similar ranges for SOX2 ampliﬁca-
tion of between 11% and 32% of examined tumors as
found in our study for vulvar cancer. Data on SOX2
protein overexpression are also limited in vulvar
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carcinomas. Brustmann and Brunner (26) examined
SOX2 expression in a cohort of 33 vulvar carcinomas
and precursor lesions. In their study, SOX2 was
expressed in 72.7% of invasive carcinomas compared
with only 27.3% in our present analysis. This
diﬀerence may be due to the smaller sample size of
the other cohort and our tissue microarray approach,
which could lead to identiﬁcation of a lower
expression frequency. Interestingly, Brustmann and
Brunner also observed SOX2 overexpression espe-
cially in poorly diﬀerentiated carcinomas. Our
immunohistochemical SOX2 expression results are
comparable to those of oral SCC (24,27).
The proportion of 45.7% HPV-associated carcino-
mas in our cohort was similar to that in previous
studies (28–30). There was a striking link between
SOX2 ampliﬁcation/overexpression and HPV posi-
tivity of vulvar carcinomas in our analysis. Further-
more, immunohistochemically detectable SOX2
upregulation was connected to basaloid diﬀerentia-
tion of vulvar carcinomas. The known relationship
between HPV, basaloid phenotype of carcinomas,
and poor diﬀerentiation was clearly reproducible in
our data set (31). Thus, the connection of SOX2
ampliﬁcation and overexpression to basaloid and
poorly diﬀerentiated carcinomas also argues toward a
possible relationship between HPV status and SOX2
aberrations in vulva tumors. Interestingly, similar
SOX2 expression levels were found in morphologi-
cally and immunohistochemically characterized vul-
var intraepithelial neoplasias of classic (HPV
associated) and diﬀerentiated types (HPV independ-
ent), respectively (26). However, we detected SOX2
overexpression and ampliﬁcation only in a minor
subset of HPV-negative invasive vulvar carcinomas.
TABLE 1. Relationships between SOX2 copy number as well as SOX2 expression and clinicopathologic features in vulvar
carcinomas
SOX2 FISH SOX2 IHC
All (n) Disomy (n) Ampliﬁcation (n) Low Level (n) High Level (n) P
Samples 55 38 10 40 15
Age (y)
Median 69 70 63.5 68 70 NS
Histologic tumor type
Keratinizing 26 20 4 21 5 NS/Po0.05
Nonkeratinizing 23 15 4 18 5
Basaloid 6 3 2 1 5
Tumor stage
pT1a 4 3 1 3 1 NS
pT1b 31 20 6 24 7
pT2 10 9 7 3
pT3 4 4 2 2
pT4 3 1 2 1 2
Nodal stage
pN0 17 12 3 11 6 NS
pN1a,b 5 4 5
pN2a-c 10 6 3 8 2
Grading
G1 6 6 6 0 Po0.05/NS
G2 29 23 2 22 7
G3 16 7 6 9 7
HPV
Negative 25 19 2 21 4 Po0.05
Positive 21 12 8 11 10
FISH indicates ﬂuorescence in situ hybridization; HPV, human papillomavirus; IHC, immunohistochemistry; NS, not signiﬁcant.
FIG. 1. Keratinizing squamous cell carcinoma of the vulva
showing low-level amplification of the SOX2 gene: red signals
indicate copy number of chromosome 3 and green signals indicate
SOX2 copy number. (Magnification  400 with zoomed-up inset).
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Molecular characterization of HPV association of
invasive carcinomas in the present study may explain
the analytical diﬀerences (32).
The molecular events in HPV-driven vulvar tumors
and HPV-negative carcinomas are quite diﬀerent.
Ampliﬁcations of canonical cancer genes such as
EGFR and CCND1 seem to mostly arise in HPV-
unrelated carcinomas (33). In this type of vulvar
carcinoma, TP53 mutations play a crucial role in
cancer progression. HPV-related tumorigenesis is
driven by viral oncogenes E6 and E7 that disrupt the
retinoblastoma pathway in tumor cells. However, there
are some hints that the insertion of HPV in the host
genome is not random. Studies in head and neck
carcinomas showed possible relations between inser-
tion loci and ampliﬁcation of associated genes, whereas
only low levels of E6 or E7 are observed (34). These
observations could explain the preferential ampliﬁca-
tion of speciﬁc genes, including SOX2, in HPV-related
cancers. In addition, the linkage between SOX2
ampliﬁcation and G3 status of vulvar cancer may be
the sequel of genomic instability in these cancers.
The 2016 WHO classiﬁcation newly separated penile
carcinomas in HPV-positive and HPV-negative SCC.
Subtypes of HPV-positive penile carcinomas were
basaloid SCC, warty SCC, and warty-basaloid SCC.
Our study conﬁrmed that the basaloid phenotype is
linked to HPV infection in vulvar SCC also. Data on
molecular alterations in penile carcinomas are lim-
ited (35). Recently we could demonstrate that ampli-
ﬁcation and overexpression of CCND1 at 11q is related
to HPV-negative vulvar carcinomas (36). Therefore, it
is tempting to speculate that SOX2 alterations are
more relevant for HPV-positive SCC, whereas CCND1
is involved in the progression of HPV-negative SCC in
vulvar and in penile cancer (37). A future WHO
classiﬁcation of vulvar SCC could be therefore adapted
to the penile WHO classiﬁcation.
In summary, the data of this study show that SOX2
is variably ampliﬁed in vulvar cancers and is related
to HPV-driven carcinogenesis in vulvar carcinomas.
FIG. 2. Examples of SOX2 immunohistochemistry results in vulvar carcinomas: weak (A), moderate (B), and strong (C) expression.
TABLE 2. Correlation of SOX2 copy number alterations
and the respective protein expression in vulvar carcinomas
SOX2 FISH
Disomy (n) Ampliﬁcation (n) P
SOX2 IHC
Low level 32 3 o0.01
High level 6 7
FISH indicates ﬂuorescence in situ hybridization; IHC, immu-
nohistochemistry.
FIG. 3. Prognostic significance of SOX2 amplification and SOX2
expression level in vulvar carcinomas.
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The speciﬁc role of SOX2 in combination with other
lineage-speciﬁc genes in SCCs makes it suitable as a
therapeutic target in a broad range of cancers,
including vulvar carcinoma (38).
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